Clinical Trial Update: Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of masitinib (AB1010) in mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: AB Science | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED